News ESC: MSD/Bayer's Verquvo disappoints in heart failure trial Bayer and MSD's hopes of expanding the use of Verquvo in heart failure have been dashed by a failed phase 3 trial.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
